LIF R

LIF R

LIF R Molekülinformation

Molecule Name
Leukemia inhibitory factor receptor
Molekülalias
LIFR,CD118,FLJ98106,FLJ99923,SJS2,STWS,SWS
Drug Development Progress
Anzahl der klinischen Arzneimittel2
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Target-Alias
LIF receptor,LIF-R,CD118
Molekülhintergrund
Leukemia inhibitory factor receptor is also known as LIFR; CD118; FLJ98106; FLJ99923; LIF-R; SJS2; STWS; SWS, is the receptor for leukemia inhibitory factor (LIF). The leukemia inhibitory factor is a polyfunctional cytokine that affects the differentiation, survival, and proliferation of a wide variety of cells in the adult and the embryo. LIF action appears to be mediated through a high-affinity receptor complex composed of a low-affinity LIF binding chain (LIF receptor) and a high-affinity converter subunit, gp130. Both LIFR and gp130 are members of a family of cytokine receptors that includes components of the receptors for the majority of hematopoietic cytokines and for cytokines that affect other systems, including the ciliary neurotrophic factor, growth hormone and prolactin Defects in LIFR are the cause of Stueve-Wiedemann syndrome (SWS), a severe autosomal recessive condition and belongs to the group of the bent-bone dysplasias.

LIF R Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Cardiotrophin-1 (Digna Biotech/Biotecnol)CT-1Phase 2 ClinicalBiotecnol Sa, Digna Biotech Sl, Genentech Inc
Acute Kidney Injury; Ischemia; Liver Failure; Myocardial Reperfusion Injury
Details
MSC-1 (Northern Biologics)Phase 1 ClinicalMosaic Biosciences
Carcinoma, Non-Small-Cell Lung; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours
Details